NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cara Therapeutics Inc. (NASDAQ: CARA), Sigma Designs Inc. (NASDAQ: SIGM), Pep Boys-Manny Moe and Jack (NYSE: PBY) and Nektar Therapeutics (NASDAQ: NKTR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
To access our full PDF Research Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
CARA Research Package: http://www.traders-choice.com/pdf?s=CARA
SIGM Research Package: http://www.traders-choice.com/pdf?s=SIGM
PBY Research Package: http://www.traders-choice.com/pdf?s=PBY
NKTR Research Package: http://www.traders-choice.com/pdf?s=NKTR
============
Highlights from today's reports include:
On Friday, December 18, 2015, NASDAQ Composite ended at 4,923.08, down 1.59%, Dow Jones Industrial Average declined 2.10% to finish the day at 17,128.55 and the S&P closed at 2,005.55, down 1.78%.
- Cara Therapeutics Inc.'s stock edged higher by 0.13% to close Friday's session at USD 15.34. The stock traded above its 50-day and 200-day moving averages of USD 15.30 and USD 14.52, respectively. The company’s shares oscillated between USD 15.12 and USD 15.82. The stock recorded a trading volume of 0.301 million shares, which was below its 50-day daily average volume of 0.302 million shares and above its 52-week average volume of 0.294 million shares. Over the last three days, Cara Therapeutics Inc.'s shares have advanced 0.07% and in the past one week, the stock has moved up 1.12%. Over the last three months, the stock has lost 29.28% whereas in the past six months, the shares have picked up 35.75%. Moreover, Cara Therapeutics Inc. is trading at a price to book ratio of 3.70 and Price/Sales TTM ratio of 76.4.
- The stock of Sigma Designs Inc. gained 3.74% to close Friday's session at USD 6.38. The shares of the company moved in the range of USD 6.09 and USD 6.44. A trading volume of 0.92 million shares was recorded, which was greater than its 150-day daily average volume of 0.67 million shares and above its 52-week average volume of 0.56 million shares. Over the last five days, Sigma Designs Inc.'s shares have advanced 1.27% while in the past one month, the shares have lost 22.95%. Additionally, over the last three months, the stock has declined 10.52% and in the past six months, the shares have registered a loss of 48.00%. The stock traded much below its 50-day and 200-day moving averages of USD 8.22 and USD 8.96, respectively. Further, the company is trading at a price to cash flow ratio of 5.54, whereas the price to sales ratio was recorded at 1.01.
- Pep Boys-Manny Moe and Jack's stock decreased by 0.25% to close Friday's session at USD 15.76, above its 50-day and 200-day moving averages of USD 14.82 and USD 11.92, respectively. The company's shares fluctuated in the range of USD 15.76 and USD 15.95. A total of 2.02 million shares exchanged hands, which surpassed its 50-day daily average volume of 1.62 million shares and was above its 52-week average volume of 0.68 million shares. Over the last three days, Pep Boys-Manny Moe and Jack's shares have declined by 1.38% and in the past one week, the shares have moved down 3.55%. However, over the last three months, the stock has gained 34.36% and in the past six months, the shares have picked up 35.16%. On a compounded total return basis, the company has returned 4.79% in the last one month. In addition, the stock is trading at a price to book ratio of 1.56, as against the historical PB ratio of 0.86.
- Nektar Therapeutics's stock slipped by 0.25% to close Friday's session at USD 15.87, above its 50-day and 200-day moving averages of USD 13.60 and USD 12.12, respectively. The company's shares oscillated between USD 15.60 and USD 16.25. The stock recorded a trading volume of 3.92 million shares, which was above its 50-day daily average volume of 1.43 million shares and above its 52-week average volume of 1.50 million shares. Over the last five days, Nektar Therapeutics's shares have advanced 2.72% and in the past one month, the stock has gained a momentum of 10.44%. In addition, over the last three months, the stock has gained 14.01% and year to date, the shares have picked up 2.39%. Further, the stock is trading at a price to book ratio of 54.27, compared to the historical PB ratio of 55.98. Additionally, the stock is trading at a price to cash flow ratio of 79.27.
--
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice